Ranger Resilience and Improved Performance on Phospholipid Bound Omega-3's

NACompletedINTERVENTIONAL
Enrollment

555

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

June 30, 2018

Study Completion Date

June 30, 2018

Conditions
NutritionFatty Acids, Omega-3CognitionResilience, PsychologicalPsychology, Military
Interventions
DIETARY_SUPPLEMENT

Phospholipid-bound omega-3 supplement

The dietary supplement is produced by Aker BioMarine. These krill oil capsules received a GRAS status approval from the U.S. Food and Drug Administration (FDA) in 2010. Aker BioMarine has a new pending application (2015) with the U.S. FDA for GRAS status for its new product on which this study capsule is based. Aker BioMarine markets a number of different krill-based omega-3 supplement products in the U.S. The US Food and Drug Administration (FDA) has determined that an Investigator New Drug (IND) Application is not required for this study. This phospholipid-bound omega-3 dietary supplement is provided in capsule form.

DIETARY_SUPPLEMENT

Placebo supplement

Placebo capsules that are identical in size and color to the experimental but contain an equal amount of macadamia nut oil.

Trial Locations (3)

20892

National Institutes of Health, Bethesda

29425

Medical University of South Carolina, Charleston

31905

US Army, Fort Benning, Fort Benning

All Listed Sponsors
collaborator

Aker BioMarine Human Ingredients AS

INDUSTRY

lead

Medical University of South Carolina

OTHER

NCT02908932 - Ranger Resilience and Improved Performance on Phospholipid Bound Omega-3's | Biotech Hunter | Biotech Hunter